These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 16056009)

  • 1. Cost-effectiveness analysis: from science to application.
    Berger ML; Teutsch S
    Med Care; 2005 Jul; 43(7 Suppl):49-53. PubMed ID: 16056009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A strategic plan for integrating cost-effectiveness analysis into the US healthcare system.
    Neumann PJ; Palmer JA; Daniels N; Quigley K; Gold MR; Chao S;
    Am J Manag Care; 2008 Apr; 14(4):185-8. PubMed ID: 18402510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generalised cost-effectiveness analysis: an aid to decision making in health.
    Hutubessy RC; Baltussen RM; Torres-Edejer TT; Evans DB
    Appl Health Econ Health Policy; 2002; 1(2):89-95. PubMed ID: 14619255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Priority setting and the ethics of resource allocation within VA healthcare facilities: results of a survey.
    Foglia MB; Pearlman RA; Bottrell MM; Altemose JA; Fox E
    Organ Ethic; 2008; 4(2):83-96. PubMed ID: 18839751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention, policy, and paradox: what is the value of future health?
    Ganiats TG
    Am J Prev Med; 1997; 13(1):12-7. PubMed ID: 9037337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Criteria and procedures for determining benefit packages in health care. A comparative perspective.
    Gress S; Niebuhr D; Rothgang H; Wasem J
    Health Policy; 2005 Jul; 73(1):78-91. PubMed ID: 15911059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and implementation of health technology assessment in Argentina: two steps forward and one step back.
    Rubinstein A; Pichon-Riviere A; Augustovski F
    Int J Technol Assess Health Care; 2009 Jul; 25 Suppl 1():260-9. PubMed ID: 19527545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Why don't Americans use cost-effectiveness analysis?
    Neumann PJ
    Am J Manag Care; 2004 May; 10(5):308-12. PubMed ID: 15152700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacoeconomics.
    Ahuja J; Gupta M; Gupta AK; Kohli K
    Natl Med J India; 2004; 17(2):80-3. PubMed ID: 15141600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health system and equity perspectives in health technology assessment.
    Hanvoravongchai P
    J Med Assoc Thai; 2008 Jun; 91 Suppl 2():S74-87. PubMed ID: 19253490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Limitations of acceptability curves for presenting uncertainty in cost-effectiveness analysis.
    Groot Koerkamp B; Hunink MG; Stijnen T; Hammitt JK; Kuntz KM; Weinstein MC
    Med Decis Making; 2007; 27(2):101-11. PubMed ID: 17409361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How should cost-effectiveness analysis be used in health technology coverage decisions? Evidence from the National Institute for Health and Clinical Excellence approach.
    Williams I; Bryan S; McIver S
    J Health Serv Res Policy; 2007 Apr; 12(2):73-9. PubMed ID: 17407655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A policy case study of blood in Australia.
    Graves N; Clare G; Haines M; Bird R
    Soc Sci Med; 2010 Nov; 71(9):1677-82. PubMed ID: 20843593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploring policy-makers' perspectives on disinvestment from ineffective healthcare practices.
    Elshaug AG; Hiller JE; Moss JR
    Int J Technol Assess Health Care; 2008; 24(1):1-9. PubMed ID: 18218163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reflections on science, judgment, and value in evidence-based decision making: a conversation with David Eddy by Sean R. Tunis.
    Eddy D
    Health Aff (Millwood); 2007; 26(4):w500-15. PubMed ID: 17580317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Public healthcare resource allocation and the Rule of Rescue.
    Cookson R; McCabe C; Tsuchiya A
    J Med Ethics; 2008 Jul; 34(7):540-4. PubMed ID: 18591290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk aversion and uncertainty in cost-effectiveness analysis: the expected-utility, moment-generating function approach.
    Elbasha EH
    Health Econ; 2005 May; 14(5):457-70. PubMed ID: 15386661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence-based decision-making within Australia's pharmaceutical benefits scheme.
    Lopert R
    Issue Brief (Commonw Fund); 2009 Jul; 60():1-13. PubMed ID: 19639714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of context on evidence utilization: a framework for expert groups developing health policy recommendations.
    Dobrow MJ; Goel V; Lemieux-Charles L; Black NA
    Soc Sci Med; 2006 Oct; 63(7):1811-24. PubMed ID: 16764980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.